Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG‐MESRAT study

Documenti analoghi

• Peripheral blood profiling of azacitidine's hypomethylation: Advancing precision medicine in juvenile chronic myelomonocytic leukaemia
  di: Pasquale Niscola
  Pubblicazione: (2025)
• Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial
  di: Franco Locatelli, et al.
  Pubblicazione: (2024)
• Chronic myelomonocytic leukaemia
  di: Ayalew Tefferi, et al.
  Pubblicazione: (2025)
• Facial pustular eruption of chronic myelomonocytic leukaemia
  di: Ying Zhao, et al.
  Pubblicazione: (2026)
• Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia
  di: Julia A. Meyer, et al.
  Pubblicazione: (2025)